Category Archives: Psoriasis

United States of America:-The Interleukin market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

The global Interleukin market size is expected to gain market growth in the forecast period of 2020 to 2026, with a CAGR of xx% in the forecast period of 2020 to 2026 and will expected to reach USD xx million by 2026, from USD xx million in 2019.

Under COVID-19 Outbreak, how the Interleukin Industry will develop is also analyzed in detail in COVID Impact Chapter of this report.

For Better Understanding, Download FREE Sample Copy of Interleukin Market Report(Including full TOC, Graphs, Sample Data, and Tables)@ https://www.marketreportexpert.com/report/Interleukin/36243/sample

Some of top players influencing the Global Interleukin market:

Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Others

Note: We can provide market report in regional language too, German/French/Japanese. We have researched the situation of COVID-19 thoroughly and Our new sample has been updated to reflect COVID-19 Impact on industry trends. We also offer a 25% discount.

Market segmentation

Interleukin market is split by Type and by Application. For the period 2015-2026, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Majortype, primarily split into

Pharmaceuticals and Healthcare

Major applications/end users, including

IL-17IL-23IL-1IL-5IL-6Others

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert(Note: Our reports include the analysis of the impact of COVID-19 on this industry. Our updated sample pages shows impact of Covid-19 on Industry trends.): https://www.marketreportexpert.com/report/Interleukin/36243/inquiry

This report examines all the key factors influencing growth of global Interleukin market, including demand-supply scenario, pricing structure, profit margins, production and value chain analysis. Regional assessment of global Interleukin market unlocks a plethora of untapped opportunities in regional and domestic market places. Detailed company profiling enables users to evaluate company shares analysis, emerging product lines, scope of NPD in new markets, pricing strategies, innovation possibilities and much more.

The Interleukin market is analysed and market size information is provided by regions (countries).

The key regions covered in the Interleukin market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Regional analysis is another highly comprehensive part of the research and analysis study of the global Interleukin market presented in the report. This section sheds light on the sales growth of different regional and country-level Interleukin markets. For the historical and forecast period 2015 to 2026, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Interleukin market.

Get Table of Content, Tables, and Figures of Interleukin Market Report: https://www.marketreportexpert.com/report/Interleukin/36243/tableofcontent

Some of the key questions answered in this report:

What will the market growth rate, growth momentum or acceleration market carries during the forecast period?Which are the key factors driving the Interleukin market?What was the size of the emerging Interleukin market by value in 2020?What will be the size of the emerging Interleukin market in 2026?Which region is expected to hold the highest market share in the Interleukin market?What trends, challenges and barriers will impact the development and sizing of the Global Interleukin market?What is sales volume, revenue, and price analysis of top manufacturers of Interleukin market?What are the Interleukin market opportunities and threats faced by the vendors in the global Interleukin Industry?

The reports conclusion leads into the overall scope of the Global market with respect to feasibility of investments in various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the Global Interleukin market in the near future. The report will assist understand the requirements of customers, discover problem areas and possibility to get higher, and help in the basic leadership manner of any organization. It can guarantee the success of your promoting attempt, enables to reveal the clients competition empowering them to be one level ahead and restriction losses.

About Us

Market Report Expert is a futuristic market intelligence company, helping customers flourish their business strategies and make better decisions using actionable intelligence. With transparent information pool, we meet clients objectives, commitments on high standard and targeting possible prospects for SWOT analysis and market research reports.

Contact USJames ThompsonMarket Report ExpertPhone: +1-816-301-6258Email [emailprotected]Web:-https://www.marketreportexpert.com

https://factorygate.co.uk/

Read the original here:
Global Interleukin Market Analysis, Size, Trends and Forecast to 2026 | Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma - Factory Gate

Market Insights:

Psoriasis is a highly common chronic skin condition. Market Research Futures (MRFR) in-depth market report on the global psoriasis treatment market has disclosed that the market is anticipated to witness a promising CAGR of 7.3% during the forecast period of 2016 to 2022. The social stigma and discomfort that is associated with psoriasis is expected to promote swift market growth. Valued at USD 7 Bn at the beginning of 2016, the global market is expected to witness increased revenue which results in an approximate evaluation of over USD 10 bn by the end of the assessment period.

Free PDF Sample @ https://www.marketresearchfuture.com/sample_request/2769

Rising awareness and screening for psoriasis is the leading factor driving growth in the demand for psoriasis treatment. This chronic condition is exacerbated by several factors which can vary from patient to patient, thus further increasing the demand for appropriate and effective treatment options. Increasing exposure to chemicals and polluted environments have resulted in an increase in the diagnosis of psoriasis. Presently, all treatment options are temporary in nature or need ongoing patient involvement with no concrete cure. Drugs for psoriasis treatment carry a high cost which will hamper market growth. However, increasing adoptions of alternative psoriasis treatments, and the race among market players to develop an effective psoriasis treatment solution will lead to market opportunities.

Key Players:

Market leaders who participate in the competitive landscape of the global psoriasis treatment market include Eli Lilly, Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co Inc., Amgen and AbbVie.

Latest Industry News:

Eli Lilly & Company in Korea has received government approval from the Ministry of Health & Welfare for the reimbursement for its psoriasis treatment drug Taltz.

Market Segmentation:

The global psoriasis treatment market is segmented in MRFRs competitive analysis on the basis of mechanism of action, route of administration, drug types, and region. Based on mechanism of action, the market is segmented into interleukin blockers, phosphodiesterase inhibitors, TNF inhibitors, and others.

By route of administration, the market is divided between oral, injectable, and topical. Oral treatment options are highly popular and capture around 40% of the global market.

On the basis of drug types, the market is segmented into biologics and small molecules.

Globally, the market is divided into the Americas, Europe, Asia-Pacific (APAC), and the Middle East and Africa.

Browse Full Report @ https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769

Regional Analysis:

Due to the presence of North America, the Americas account for the largest share of the global market. The presence of several market players and a high patient population afflicted with psoriasis is expected to lead to increased revenue generated for market growth. Moreover, the awareness about this condition is quite high in the region and has led to an increased demand for effective treatment options. Increasing R&D activities to develop a long-term solution for psoriasis is expected to facilitate market expansion opportunities.

Meanwhile, the Asia Pacific is the fastest growing region due to the swiftly developing healthcare sector and the growing awareness regarding conditions like psoriasis which has resulted in increased demand. The affinity for natural skin care methods is expected to reveal effective alternate treatment strategies that may assist future market growth.

related reports

Wearable Sensors Market

https://www.openpr.com/news/2092665/wearable-sensors-market-outlook-covid19-impact-2020

Biosensors Market

https://www.openpr.com/news/2092666/covid-19-analysis-on-biosensors-market-2020-industry-acquire

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services

https://neighborwebsj.com/

See the original post:
Psoriasis Treatment Market Share, Demand, New Opportunities and Foresight to 2022 - NeighborWebSJ

Johnson & Johnson (NYSE:JNJ) is trailing the leaders in the coronavirus vaccine race, but the healthcare giant is approaching the finish line, thanks to cutting the size of its phase 3 clinical trial. In this video from Motley Fool Live, recorded on Dec. 21, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the implications of the smaller clinical trial. They also talk about whether it makes sense to invest in Johnson & Johnson specifically for its vaccine candidate.

Corrine Cardina: So Johnson & Johnson announced that they have completed enrollment for their trial, for their one-dose vaccine candidate. They actually ended up lowering the target number of participants in the study. What drove that decision and does it have any implications, Brian?

Brian Orelli: Yes. They were planning for 60,000 patients and then they lowered it to 45,000 patients. This is an event-driven clinical trial. Most clinical trials are time-driven. If you think of something like psoriasis, rheumatoid arthritis, you treat for a certain amount of time and then at the end of that time, you see whether the symptoms improved. Events-driven trials are measuring a certain event. So in the case of a vaccine, that's infections. Cancer trials are also usually run as event-driven clinical trials, and then you're looking at survival or progression of the disease. You run the trial, you count the number of events, and the trial is blinded so you don't know whether those are occurring in the placebo group or in the treatment group. Then after you get to a certain number of events, then you unblind it, and look and see do these people get treatment or do they get vaccines.

If the infection rate is higher, which it is, than when they first started the clinical trial. Then trials can be smaller because the number of events will happen sooner. If it is a very rare event, then you need more patients than if it is a more likely event. Then also, if the efficacy is higher, then the trials can be smaller. If you were looking at 200 events, and it was going to be 90 and 110, you don't know whether that's necessarily a difference, but because other vaccines were so good, they may have also decided that they're more likely to get a bigger separation, it's going to be the 190 and 10 out of 200. The breakdown is pretty obvious if the vaccines work.

Cardina: Definitely. So when should we look for data from Johnson & Johnson's phase 3 trial? Do you have any estimates for timeline on regulatory submission?

Orelli: Yeah. The interim data Johnson & Johnson have said, they expect the data by the end of January. But again, it's event-driven, so it's going to depend on when people actually get infected and whether they're going to get infected in the placebo group or the vaccine group. If that happens, then they're planning on submitting, the emergency use the authorization to the FDA in February, and they'll do other countries in parallel. I think they probably need some more additional safety data. That's why they can't quite do it at the end of January. Then it will take a few weeks for the FDA to review it. They didn't say when in February they would be ready, so it could be as early as they could get approved or authorized as early as late February, and maybe as late as the second half of March.

Cardina: Definitely. One thing investors should know is that Johnson & Johnson has pledged not to profit on this vaccine during the pandemic. How does that factor into any sort of investment decision into Johnson & Johnson?

Orelli: It goes back to that same immunity question. We just don't know how long the vaccine is going to last. If it's a one and done, there's enough herd immunity that the virus goes away, then obviously they're not going to benefit at all. If it requires that we get a booster every year, four years, five years, to 10 years, then it will obviously benefit a little bit. Johnson & Johnson is huge, well diversified. I wouldn't invest for the coronavirus, but it doesn't mean you shouldn't invest in Johnson & Johnson if you're looking for a solid diversified healthcare investment with a solid dividend that just keeps going up.

Excerpt from:
Why Did Johnson & Johnson Cut the Size of Its Coronavirus Vaccine Trial? - The Motley Fool

News Release

Monday, December 28, 2020

Psoriasis, a chronic inflammatory skin disease, has long been known to increase the risk of cardiovascular disease, which includes heart attack and stroke. Now, researchers have identified a key culprit: the presence of metabolic syndrome (MetSyn), a condition that includes obesity, diabetes, high cholesterol, and hypertension, and is highly prevalent among psoriasis patients.

The findings, which could lead to new ways to help prevent cardiovascular disease among people with psoriasis, appear online today in the Journal of the American Association of Dermatology (JAAD). The study was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Metabolic syndrome, so common among our psoriasis patients, drives up coronary artery disease in this population by increasing the plaque buildup that clogs the hearts arteries, said Nehal N. Mehta, M.D., MSCE, preventive cardiologist and head of the NHLBIs Lab of Inflammation and Cardiometabolic Diseases. Our study shows that, of the MetSyn components, hypertension and obesity contribute the most to coronary plaque buildup, and hence can be good targets for intervention.

Partly because it worsens vascular and systemic inflammation, psoriasis, a common skin disease affecting 2-3% of adults, not only increases but speeds up atherosclerosis, the plaque buildup that clogs arteries and can lead to heart attack and stroke. Metabolic syndrome affects about 25% of adults and is on the rise, and its prevalence is even greater among patients with psoriasis.

To reach their conclusions, Mehta and his team conducted an observational study of the NIH Psoriasis, Atherosclerosis, and Cardiometabolic Initiative cohort, which included 260 patients with psoriasis, 80 of whom met the criteria for metabolic syndrome. All participants underwent CT scanning to take pictures of their coronary arteries using a technique called cardiac computed tomography angiography (CTA).

The study found that systemic inflammation, insulin resistance, and blood cholesterol were significantly higher in the participants who had both psoriasis and metabolic syndrome. And those with MetSyn had higher coronary artery plaque buildup, assessed by CTA, which is a high-risk factor for heart attacks.

Even after adjusting for individual MetSyn factors, blood pressure and obesity assessed by waist circumference were the most significant links to coronary plaque buildup, Mehta explained.

Obesity is the most salient aspect of MetSyn, and excess visceral fat tissue, technically known as visceral adipose tissue (VAT), plays a large role in it, the researchers concluded after the amount of VAT measured by CT scans was associated to MetSyn factors such as waist circumference, blood pressure, triglycerides, high cholesterol.

VAT is a known predictor of cardiovascular disease in the general population, as well as a predictor of increased plaque buildup in psoriasis patients. However, due to the needed imaging technology, measuring VAT is not currently feasible in a doctors office.

This new study, Mehta said, demonstrates a critical link between excessive VAT and metabolic syndrome in psoriasis patients. It suggests that identifying metabolic syndrome, especially waist circumference, can significantly help in estimating VAT and assessing cardiovascular disease risk in clinical settings for patients with psoriasis.

It also showed for the first time, he said, the impact of metabolic syndrome on early vascular disease in psoriasis patients, measured through the plaque buildup.

In psoriasis patients, traditional risk factors of cardiovascular disease, such as age, do not relate strongly to cardiovascular risk as in the general population, Mehta said. However, he added, the findings in the study show the importance of evaluating for the presence of the metabolic syndrome as a heretofore unexplored risk factor.

Because this was an observational study, the researchers cannot establish cause-effect links, Mehta noted. But the new research provides strong evidence that psoriasis patients with metabolic syndrome have high levels of disease-producing plaque.

About the National Heart, Lung, and Blood Institute (NHLBI): NHLBI is the global leader in conducting and supporting research in heart, lung, and blood diseases and sleep disorders that advances scientific knowledge, improves public health, and saves lives. For more information, visit http://www.nhlbi.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Mehta, N. et al.Metabolic Syndrome and its Factors are Associated with Non-Calcified Coronary Plaque Burden in Psoriasis: An Observational Cohort Study.DOI:

###

Continued here:
Study links metabolic syndrome to higher cardiovascular risk in patients with psoriasis - National Institutes of Health

SINGAPORE, Dec. 30, 2020 /PRNewswire/ -- Psoriasis causes skin cells to multiply up to 10 times faster than normal,causing skin build up into red patches covered with white scales affecting largely the scalp, elbows and knees. It is estimated that more than 125 million of the world's population is affected by this condition and people of Caucasian descent is 4 times more likely to contract this condition than Asian. Up to 60% of people with Psoriasis, particularly with women and younger patients, reported that their condition has a negative social impact in their lives. Whilst there is no cure available for Psoriasis, it is shown that topical agents when applied directly can bring this condition under control.

QTH Group is one ofthree company groups that specializes in Psoriasis, hence their products are produced with a specific target at this condition. QTH has a team of 50 dermatologists and over 100 researchers behind their range of products specifically produced to help people who suffer from Psoriasis. QTHrange of products are 100% natural, only using plant extracts. No animal ingredients or testing are used in the process of production.

QTH is pleased to announce the launch of their product range to the American market. Their product range consist of shampoo, scalp essence, body scrub,body lotionand anti-acne cream. All products are meant for topical use and application, the best methodology that is proven to be effective for this condition. The key ingredients that runs through their products is the right percentage blend of Salicylic Acid, which is extracted from white willow. QTH team of specialists have discovered that the right percentage of Salicylic Acid,used as one of the main ingredients,iskey to faster rate of relief and recovery.

Other key ingredients such as Argan Oil is used in QTHscalp essence and itis known for its healing and anti-inflammatory properties. Dead Sea Salt, known for their antifungal and antibacterial properties, is used in QTHbody scrub.

QTH'svision is to make their productsreadily available to all who needsthem.Hence, the sourcing of ingredients and production, whilst not compromising the high standards of productions, cost are kept efficient, to enable affordability. QTH products are available on https://www.amazon.com/qthand https://www.amazon.com/dp/B08MBM9RQ1

Media Contact ELPIS @ Hideout Pte LtdMs Lily Low[emailprotected](65) 82283339

SOURCE QTH Health

Read the rest here:
QTH Introduces Revolutionary Hair and Body Products for Effective Control of Psoriasis - PRNewswire

Coherent Market Insights announced that its published an exclusive report namely Global Psoriasis Treatment Market by Manufacturers, Regions, Type, and Application, Forecast to 2027 in its research database with report summary, table of content, research methodologies, and data sources. The research study offers a substantial knowledge platform for entrants and investors as well as veteran companies, manufacturers functioning in the Worldwide Psoriasis Treatment Market. This is an informative study covering the market with an in-depth analysis and portraying the current state of affairs in the industry.

Download FREE PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/99

The report presents an overview of Psoriasis Treatment Market consist of objectives study and definition of Psoriasis Treatment. The next section focuses on market size, region-wise Psoriasis Treatment growth rate estimation from 2020-2027.

This research report categorizes the global market by players/brands, regions, types, and applications. This report also studies the global market status, competition landscape, Market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors, and Porters Five Forces Analysis.

Key Manufacturers Analysis:Glenmark Pharmaceuticals Limited, Sun Pharmaceuticals Industries Ltd., Cipla Ltd., Johnson & Johnson, Rowan Bioceuticals Private Limited, Stiefel Laboratories Inc. (GlaxoSmithKline plc), Win Medicare Pvt. Ltd., and Novartis AG

The top manufacturers, exporters, and retailers (if applicable) around the world are analyzed for this research report with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Psoriasis Treatment Market 2020 Forecast to 2027 Market Segment by Regions, regional analysis covers

Following market aspects are enfolded in Global Psoriasis Treatment Market Report:

A wide summarization of the Global Psoriasis Treatment Market. The present and forecasted regional market size data based on applications, types, and regions. Market trends, drivers, and challenges for the Global Psoriasis Treatment Market. Analysis of company profiles of Top major players functioning in the market.

Buy This Research Study Report For Quick [emailprotected] https://www.coherentmarketinsights.com/insight/buy-now/99

Psoriasis Treatment Market report passes on a fundamental overview of the Market including its definition, applications, and advancement. Furthermore, the Industry report investigates the ecumenical Major Psoriasis Treatment Market players in detail. Psoriasis Treatment Market report gives key bits of the Cautiousness and subsisting status of the Players and is a basic Source obviously and heading for Companies and people energized by the Industry.

Key questions answered in Report:-

Psoriasis Treatment Business Analysis Including Size, Share, Key Drivers, Growth Opportunities and Trends 2020- 2027 Consumption Analysis of Psoriasis Treatment, Guidelines Overview and Upcoming Trends Forecast till 2027 Psoriasis Treatment Market Top Companies Sales, Price, Revenue and Market Share Outlook Psoriasis Treatment Revenue, Key Players, Supply-Demand, Investment Feasibility and Forecast 2027 Analytical Overview, Growth Factors, Demand and Trends Psoriasis Treatment by Technology, Opportunity Analysis and Industry Forecasts, 2020- 2027 Analysis Covering Market Size, Growth Factors, Demand, Trends and Forecast Psoriasis Treatment Overview, Raw Materials Analysis, Market Drivers and Opportunities In-depth Research on Market Size, Trends, Emerging Growth Factors and Forecasts.

Conclusively, this report will provide you a clear view of each fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us

Mr. ShahCoherent Market Insights1001 4th Ave, #3200Seattle, WA 98154Phone: US +12067016702 / UK +4402081334027Email: [emailprotected]

****Stay Home. Stay Safe****

Read more from the original source:
Psoriasis Treatment Market to Witness an Outstanding Growth During 2020 2027 - Factory Gate

2020 was a significant year in rheumatology. Here are the top stories covered by DocWire News this year. Like last year, stories of interest were drug comparisons among medications treat rheumatic diseases; new to the top 10 are stories about the connection between rheumatic diseases and COVID-19, as well as ever-emerging research into how drugs used to treat rheumatic diseases may be repurposed for COVID-19 treatment.

This story makes the list for the second year in a row! In 2019, AbbVie announced that the Food and Drug Administration (FDA) approved its rheumatoid arthritis (RA) drug Rinvoq (upadacitinib). Rinvoq is an oral Janus kinase (JAK) inhibitor designed for the treatment of moderate to severe RA in patients who did not respond or have an intolerance to methotrexate. The company reported at the time that the JAK inhibitor would be available in the United States in August of 2019. Read on to see how DocWire compared Rinvoq to competitors fellow JAK inhibitors Olumiant and Xeljans, manufactured by Eli Lilly and Pfizer, respectively.

How Does AbbVies RA Drug Rinvoq Compare to Competitors?

There were a lot of stories on the connection between rheumatic diseases and COVID-19. One such study found that hospitalized COVID-19 patients with connective tissue diseases may be at risk for increased illness severity, but inflammatory arthritis may not have the same effect.

Do Inflammatory and Autoimmune Rheumatic Diseases Affect COVID-19 Illness Severity?

2019s reigning number one story comes in at number three this year. Following the FDAs approval of its approval of its osteoporosis drug romosozumab-aqqg (Evenity), Amgen announced the medication would be available in the United States at $1,825 per monthly dose, or $21,900 for a full, one-year course of treatment. Fellow bone-building competitors include Radius Health Inc.s Tymlos and Eli Lilly and Co.s Forteo, both of which also have longer courses of treatment. Read on to see how these three drugs compare in cost.

How Does Amgens Osteoporosis Drug EVENITY Compare to Competitors?

Respiratory viral infections may put patients at risk for developing RA, suggesting concerns for patients who develop coronavirus, according to a report published in August 2019 that resurfaced amid the current coronavirus pandemic. An association was observed between ambient respiratory viral infections in the population and an increase in incident RA over time, with a peak at six to seven weeks following exposure. The three viruses most associated with an increase in incident RA were parainfluenza virus (4.8% for 1% respiratory viral infection increase), coronavirus (9.2%), and metapneumovirus (44%). Patients who were impacted the most were women (3.8%, 12.1%, and 67.4%, respectively) and older patients (10.7%, 14.6%, and 118.2%, respectively).

Coronavirus May Be a Risk Factor for Rheumatoid Arthritis

Another veteran story from 2019. Last year, the FDA expanded the indication of Eli Lilly and Companys Taltz (ixekizumab) to include active ankylosing spondylitis (AS). The humanized interleukin-17A antagonist initially received approval in 2016 for the treatment of plaque psoriasis, and in 2017 of active psoriatic arthritis (PsA). It now competes with Novartis Cosentyx (secukinumab), which is indicated to treat the same three rheumatic diseases. Cosentyx garnered FDA approval in 2015 for the treatment of plaque psoriasis, and picked up the subsequent approvals for AS and PsA in 2016. Learn more here.

Taltz vs. Cosentyx: How Do These Rheumatic Drugs Compare?

Here are the five stories rounding out the top 10 list:

Go here to see the original:
The Top 10 Rheumatology Stories in 2020 - DocWire News

Both secukinumab 300 mg and secukinumab 150 mg significantly improved signs and symptoms of axial disease in patients with psoriatic arthritis (PsA) who had inadequate response to non- steroidal anti-inflammatory drugs.

Findings from a randomized controlled trial (RCT) are making the case for using secukinumab to treat axial disease in certain patients with psoriatic arthritis (PsA). Specifically, the trial found 2 doses of the interleukin (IL)-17A inhibitor yielded significant improvements in disease signs and symptoms.

The MAXIMISE (Managing AXIal Manifestations in psoriatic arthritis with SEcukinumab) trial was the first RCT to test a biological disease modifying anti-rheumatic drugs ability to improve outcomes in axial manifestations of PsA. All patients previously had inadequate responses to at least 2 non-steroidal anti-inflammatory drugs over a 4-week period.

The axial involvement represents an unmet clinical need in determining the treatment strategy across all PsA manifestations and ultimately supports informed treatment decision-making, wrote the researchers. Additionally, patients with PsA tend to under-report axial symptoms and consequently the burden of disease might be underestimated for axial disease in such patients. As a consequence, the efficacy of a biological treatment in managing axial symptoms in PsA has been investigated only in two observational studies to date, and never in a randomized controlled setting.

A total of 425 patients completed the 52-week MAXIMISE study and received placebo or either secukinumab 300 mg or secukinumab 150 mg, both of which significantly improved responses compared with placebo after 12 weeks of treatment (63% and 66%, respectively, vs 31%).

Compared with placebo, the odds ratio of having an improved response as determined by the Assessment of SpondyloArthritis International Society (ASAS20)defined as an improvement of 20% and 1 unit on a scale of 10 in at least 3 of the 4 main ASAS domainswas 3.8 for patients receiving secukinumab 300 and 4.4 for patients receiving secukinumab 150 mg.

Responses rates for patients receiving secukinumab 300, secukinumab 150 mg, or switching from placebo to either secukinumab dose were 81%, 80%, and 75%, respectively. The responses were durable, researchers found, with patients sustaining responses through the end of the study.

In addition, MRI assessments demonstrated that secukinumab 300 mg and 150 mg significantly improved Berlin MRI scores versus placebo, providing objective evidence of reduced inflammation in both the spine and the [sacroiliac joints] for patients treated with secukinumab, authors wrote.

Researchers observed comparable types and incidences of adverse events between the monoclonal antibody and placebo. No notable differences were seen between the 2 secukinumab doses.

Reference: Baraliakos X, Gossec L, Pournara E, et al. Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis. Published online December 17, 2020. doi:10.1136/annrheumdis-2020-218808

See more here:
Secukinumab Improves Signs, Symptoms of Axial Disease in Patients With PsA - AJMC.com Managed Markets Network

It's a problem that's more than skin-deep.

About seven and a half million Americans have psoriasis and about 40% of those patients also have joint inflammation that produces painful arthritis symptoms.

Now, new research suggests one surprising potential cause for the condition and some preventive measures patients can take.

Douglas Levin struggled with psoriatic arthritis before he adopted a healthier lifestyle to help counter the inflammation caused by his disease.

"Anytime you can control it by moderating your intake of food or other things you're that much better off."

Researchers know that a problem with the immune system can trigger psoriasis.

Now, Ohio State medical dermatologist Benjamin Kaffenberger is studying a potential linkbetween poor oral health, bacterial infections in the mouth, and psoriasis.

"When your body is attempting to fight this bacteria, probably it develops a little bit of a cross-reaction with the skin at the same time," he explained.

Researchers surveyed 100 patients with psoriasis, and 165 without psoriasis about their lifestyle and diet.

The results showed that poor dental and oral health, especially gum pain was associated with psoriasis.

"Unfortunately, a lot of patients don't have good access to dental care, or maybe just are too busy at a certain time frame," said Dr. Kaffenberger.

"So, they may not be getting that message when they have this disease in the first place."

Patients who had higher fruit consumption reported less significant psoriasis.

Ohio State University researchers said that indicates fresh foods may be a protective factor.

The study also reinforced earlier studies that found family history of psoriasis, smoking and obesity could be predictors of the condition.

For Levin, lifestyle changes means psoriasis no longer controls his life.

If this story has impacted your life or prompted you or someone you know to seek or change treatments, please let us know by contacting Jim Mertens atjim.mertens@wqad.comor Marjorie Bekaert Thomas atmthomas@ivanhoe.com.

See the rest here:
YOUR HEALTH: Psoriasis and your mouth | wqad.com - WQAD.com

Woman's Doctor: Knowing the symptoms of psoriatic arthritis

Updated: 9:21 AM EST Nov 28, 2020

Hide TranscriptShow Transcript

LACEE: IN THIS MORNING'S WOMAN'S DOCTOR, KNOWING THE SYMPTOMS OF PSORIATIC ARTHRITIS, IT'S A DOUBLE WHAMMY OF AUTOIMMUNE DISORDERS. NOT ONLY DO PSORIATIC ARTHRITIS SYMPTOMS MIMIC THOSE OF PSORIASIS, LIKE PATCHES OF RED, SCALY SKIN, BUT THEY CAN ALSO CAUSE THE PAINFUL, SWOLLEN JOINTS THAT ARE COMMON WITH RHEUMATOID ARTHRITIS. THE SYMPTOMS CAN CHANGE FROM DAY TO DAY AND PERSON TO PERSON, MAKING PSORIATIC ARTHRITIS A PARTICULARLY TRICKY DISEASE TO DIAGNOSE AND MANAGE. MERCY MEDICAL CENTER DR. SADE YA KHAN SAYS THAT SYMPTOMS LEFT UNTREATED CAN LEAD TO PERMANENT JOINT DAMAGE. >> SYMPTOMS OF IT CAN BE INVOLVEMENT OF DIFFERENT AREAS OF THE SKELETON. IT COULD BE IN JOINT INVOLVEMENT, INCLUDING FINGERS AND FEET, WHICH WILL BE CONSIDERED SMALL JOINTS. IT COULD INVOLVE LARGER JOINTS, INCLUDING HIPS AND SHOULDERS. AND SOMETIMES, IT CAN ALSO AFFECT SPINE. LACEE: JOINING US THIS MORNING FROM MERCY MEDICAL CENTER, DR. JOSEPH CIO TOLA. THANK YOU FOR JOINING US. >> GOOD MORNING. LACEE: THIS SEEMS LIKE A PAINFUL CONDITION. TELL ME ABOUT THE BEGINNING SYMPTOMS OF PSORIATIC ARTHRITIS. >> IT'S SIMILAR TO REGULAR ARTHRITIS. JUST INFLAMED AND SWOLLEN, VERY SORE JOINTS. THEY GET A LOT OF FLUID BUILT UP ON THEM SOMETIMES. WE MANAGE THEM WITH CORTISONE INJECTIONS AND RELIEVING THE INFLAMMATION. LACEE: IS THIS SOMETHING THAT AFFECTS A CERTAIN GROUP MORE THAN OTHER? YOUNG OR OLD, MEN OR WOMEN? >> NO. NOT PARTICULARLY. IT CAN BE YOUNGER BECAUSE PSORIASIS CAN AFFECT YOUNGER PEOPLE. IT CAN AFFECT JOINTS AS WELL. LACEE: AT WHAT POINT IS IT TIME TO TALK TO A DOCTOR. IT CAN BE CONFUSED WITH PSORIASIS AT FIRST OR ARTHRITIS. >> WHEN SOMEBODY HAS PSORIASIS AND THEIR JOINTS BEGIN TO HURT, I THINK THAT'S THE TIME WHERE THEY NEED TO REALLY GET AGGRESSIVE WITH TREATING IT. LACEE: IN TERMS OF TREATMENT, WHERE DOES TREATMENT START FOR IT? >> IT STARTS WITH MANAGING THE INFLAMMATION. SO THEY WOULD SEE EITHER THEIR DERMATOLOGIST OR THEIR REGULAR PHYSICIAN TO GET ON ANTIINFLAMMATORY REGIMEN. AND THEN WHEN IT COMES TO THE POINT WHERE THEY'RE READY FOR AN ORTHOPEDIC SURGEON, WE BEGIN MANAGING IT BY CONTROLLING THE INFLAMMATION AT THE JOINT LEVEL WITH INJECTIONS. LACEE: WHAT KIND OF POSSIBLE SURGERY COULD THIS LEAD TO? >> IT LEADS TO JOINT REPLACEMENT. IT'S VERY SIMILAR TO RHEUMATOID ARTHRITIS. WHEN THE CARTILAGE IS ERODED ENOUGH AND THE JOINT CAN'T RECOVER, WE REPLACE IT. LACEE: IS IT SOMETHING THAT YOU CAN CURE? >> NO, IT'S JUST MANAGEMENT. IT'S MANAGEMENT OF THE INFLAMMATION. LACEE: WHAT CAN YOU DO TO PREVENT IT IN THE FIRST PLACE? >> I MEAN, I THINK YOU WANT TO BE AS HEALTHY AS POSSIBLE. ANTIINFLAMMATORY DIET AND DOING THE BEST YOU CAN TO CONTROL SUGAR AND INFLAMMATORY PRODUCTS IN YOUR LIFE STYLE. BUT THAT'S REALLY ABOUT IT. LACEE: GOT TO STAY HEALTHY. >> IT'S NOT SOMETHING WE CAN CURE. LACEE: THIS TIME OF YEAR IS HARD BECAUSE THERE'S A LOT OF SUGAR AND THAT STUFF IN FRONT OF US. THANKS FOR TAKING TIME OUT OF YOUR MORNING TO JOIN US. APPRECIATE

Woman's Doctor: Knowing the symptoms of psoriatic arthritis

Updated: 9:21 AM EST Nov 28, 2020

Psoriatic arthritis is a double-whammy of autoimmune disorders. Not only do psoriatic arthritis symptoms mimic those of psoriasis -- like patches of red, scaly skin -- but they can also cause the painful, swollen joints that are common with rheumatoid arthritis. Mercy Medical Center's Dr. Joseph Ciotola explains.

Psoriatic arthritis is a double-whammy of autoimmune disorders. Not only do psoriatic arthritis symptoms mimic those of psoriasis -- like patches of red, scaly skin -- but they can also cause the painful, swollen joints that are common with rheumatoid arthritis. Mercy Medical Center's Dr. Joseph Ciotola explains.

Continued here:
Woman's Doctor: Knowing the symptoms of psoriatic arthritis - WBAL TV Baltimore